Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
November 16 2022 - 11:06AM
Business Wire
Axonics, Inc. (Nasdaq: AXNX), a global medical technology
company that is developing and commercializing novel products for
the treatment of bladder and bowel dysfunction, today announced it
ranked No. 4 on the Deloitte Technology Fast 500, a ranking of the
500 fastest growing technology, media, telecommunications, life
sciences, fintech, and energy tech companies in North America, now
in its 28th year.
Companies were ranked based on the percentage growth in their
revenue from 2018 to 2021. Axonics reported $180.3 million of
revenue in fiscal year 2021 compared to $707,000 in fiscal year
2018, representing a growth rate of 25,401%.
This is the second year in a row of Axonics being ranked in the
top 5 fastest growing companies in North America. Last year,
Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500.
Raymond W. Cohen, chief executive officer of Axonics, said,
“Axonics is proud to be recognized as one of the fastest growing
companies in North America. The strong growth of Axonics is a
testament to the mission-driven culture of the company, the
dedication of our employees, and our commitment to continuous
innovation. We have built a company that values diversity, quality,
integrity, and teamwork. We remain focused on increasing awareness
for Axonics’ best-in-class incontinence solutions, which have the
potential to significantly improve the quality of life for millions
of adults with bladder and bowel dysfunction.”
“This year’s Technology Fast 500 list is a true reflection of
some of today’s most determined and inspiring pioneers who have
prospered by anticipating what’s next, understanding what’s needed
to succeed and driving creativity forward,” said Christie Simons,
partner, Deloitte & Touche LLP and industry leader for
technology, media and telecommunications within Deloitte’s audit
and assurance practice. “Representing all facets of technology, the
winners have shown they not only have the vision but can also
expertly manage their companies through rapid growth. We
congratulate each winner on their impressive achievements.”
About the 2022 Deloitte Technology Fast 500
Now in its 28th year, the Deloitte Technology Fast 500 provides
a ranking of the fastest growing technology, media,
telecommunications, life sciences, fintech, and energy tech
companies — both public and private — in North America. Technology
Fast 500 award winners are selected based on percentage fiscal year
revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company’s operating revenues. Companies must have base-year
operating revenues of at least US$50,000, and current-year
operating revenues of at least US$5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
About Axonics
Axonics is a global medical technology company that is
developing and commercializing novel products for adults with
bladder and bowel dysfunction. Axonics recently ranked No. 1 on the
2022 Financial Times ranking of the 500 fastest growing companies
in the Americas and No. 4 on the 2022 Deloitte Technology Fast
500.
Axonics sacral neuromodulation (SNM) systems provide adults
suffering from overactive bladder and/or fecal incontinence with
long-lived, easy to use, safe, clinically effective therapy. In
addition, the company’s best-in-class urethral bulking hydrogel,
Bulkamid®, provides safe and durable symptom relief to women with
stress urinary incontinence (SUI). Overactive bladder affects an
estimated 87 million adults in the U.S. and Europe, with an
additional 40 million adults estimated to suffer from fecal
incontinence. SUI affects an estimated 29 million women in the U.S.
alone. Axonics’ clinically proven products are offered at hundreds
of medical centers across the U.S. and abroad. Reimbursement
coverage is well established in the U.S. and is a covered service
in most European countries. For more information, visit
www.axonics.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu
Limited, a UK private company limited by guarantee (“DTTL”), its
network of member firms, and their related entities. DTTL and each
of its member firms are legally separate and independent entities.
DTTL (also referred to as “Deloitte Global”) does not provide
services to clients. In the United States, Deloitte refers to one
or more of the US member firms of DTTL, their related entities that
operate using the “Deloitte” name in the United States and their
respective affiliates. Certain services may not be available to
attest clients under the rules and regulations of public
accounting. Please see www.deloitte.com/about to learn more about
our global network of member firms.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221116005768/en/
Neil Bhalodkar Investor Relations 949-336-5293
ir@axonics.com
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axonics (NASDAQ:AXNX)
Historical Stock Chart
From Apr 2023 to Apr 2024